Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016555 · ClinicalTrials.gov registry record · Early Phase 1
Burning Mouth Syndrome: Symptoms and Management
A Early Phase 1 study of Burning Mouth Syndrome, sponsored by University of Massachusetts, Amherst.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07016555: Recruiting Early Phase 1 study of Burning Mouth Syndrome, sponsored by University of Massachusetts, Amherst.
NCT07016555 is a Early Phase 1 study of Burning Mouth Syndrome that is actively recruiting participants, run by University of Massachusetts, Amherst. The registered enrollment target is 50 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07016555, a Early Phase 1 study of Burning Mouth Syndrome, is actively recruiting participants, sponsored by University of Massachusetts, Amherst.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study aims to evaluate how an oral cooling spray, currently a commercial dietary supplement, impacts symptoms associated with burning mouth syndrome (BMS). This study will examine symptoms, frequency, and severity, along with other related side effects of BMS on food intake, enjoyment, and quality of life.
Primary Outcome
Frequency, severity, and duration of oral burn between regular treatment decreases after 2 weeks of using the oral spray
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Oral cooling spray
Study Locations (1)
Massachusetts
- UMass Amherst - Amherst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2025-12-15 |
| Phase | Early Phase 1 |
What NCT07016555 shows while recruiting
NCT07016555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Burning Mouth Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Oral cooling spray is the first listed.
NCT07016555 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07016555 about?
NCT07016555 is a clinical study titled "Burning Mouth Syndrome: Symptoms and Management". This research study aims to evaluate how an oral cooling spray, currently a commercial dietary supplement, impacts symptoms associated with burning mouth syndrome (BMS). This study will examine symptoms, frequency, and severity, along with other related side effects of BMS on food intake, enjoyment,...
What is the current status of trial NCT07016555?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2025-06-11. Estimated completion is 2025-12-15.
What conditions does trial NCT07016555 study?
This clinical trial studies the following conditions: Burning Mouth Syndrome.
What interventions are being tested in trial NCT07016555?
The interventions under investigation include: Oral cooling spray (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07016555?
This trial is sponsored by University of Massachusetts, Amherst, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07016555 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burning Mouth Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07016555's enrollment target sits among peer trials
50 493rd of 2000 higher than 1,468 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI